|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Candidate gene polymorphism in cardiovascular disease: the BIP cohort.
|
16544732 |
2006 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Concentrations of VLDL or LDL with apoC-III independently predict cardiovascular disease.
|
22301884 |
2012 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Serum apoCIII concentration was highly correlated with multiple changes in lipids and lipoproteins that resulted in an adverse cardiovascular disease risk profile.
|
15375785 |
2004 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
High plasma concentrations of triglycerides (TG) and apolipoprotein C-III (ApoC-III) are well-known risk factors for cardiovascular disease.
|
16682041 |
2007 |
|
Drug Eruptions
|
0.300 |
Biomarker
|
group |
CTD_human |
[Screening and identification of differential serum proteins related to dermatitis medicamentosa-like of trichloroethylene].
|
21055120 |
2010 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Notably, expression of alpha-2-macroglobulin, transthyretin, alpha-1-antitrypsin, and properdin was in common in different lung tumor models, but regulation of orosomucoid-8, apolipoprotein-A1, apolipoprotein-C3, apolipoprotein-E, glutathione peroxidase-3, plasma retinol-binding protein, and serum amyloid P component was unique when the serum proteomes of c-myc and c-raf tumor bearing mice were compared.
|
19180532 |
2009 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
ApoC-III-defined HDL subspecies displayed opposing associations with incidence of diabetes (p for heterogeneity = 0.02).
|
30949716 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
ApoC3 is a promising therapeutic target for hypertriglyceridemia in patients with MetS and diabetes.
|
30723097 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
APOC3 3u386 GC/GG subjects with diabetes exhibited significantly higher triglyceride (P = 0.004), total cholesterol (P = 0.003) and glucose (P = 0.016) compared to CC subjects.
|
19424489 |
2009 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, comparison between EWs with T2D and healthy EWs suggest APOC3 1100C>T is associated with increased risk of diabetes probably through mechanisms other than direct effects on TG.
|
17197160 |
2007 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Conversely, the SstI polymorphism of APOCIII gene was not significantly associated with either MI or diabetes.
|
15585206 |
2005 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ApoC-III levels determined the development of diabetes [RR 1.56 (95%CI 1.21; 2.01)] and CHD [RR 1.38 (1.10; 1.72) for an increment of 14%], after adjustment for confounders.
|
21185820 |
2011 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Considering the high prevalence of T2DM in Saudi Arabia, we sought to examine the possible association of ApoC3 gene variants with diabetes risk in Saudi population.
|
26247234 |
2015 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The cholesterol concentration of HDL (HDL cholesterol (HDL-C)) without apoC-III was inversely associated with risk of diabetes (HR = 0.48, 95% CI: 0.27, 0.85; P-trend = 0.002), more so than total HDL-C (HR = 0.60, 95% CI: 0.35, 1.03; P-trend = 0.04), whereas HDL-C with apoC-III was not associated (HR = 1.05, 95% CI: 0.50, 2.21; P-trend = 0.44) (for HDL-C with apoC-III vs. HDL-C without apoC-III, P-heterogeneity = 0.002).
|
28520887 |
2017 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Homozygosity for the APOC3 wild-type genotype (APOC3 WT) was associated with a more favorable lipid profile in control subjects, and consistently with lower hepatic APOC3 mRNA levels in obese patients without diabetes.
|
21777557 |
2011 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, in a type-1 diabetes rat model lowering of apoCIII delays onset of diabetes.
|
27875339 |
2017 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years.
|
17700364 |
2007 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Therefore, although the individual risk of hypertriglyceridemia is increased in women with the haplotype T, C at -482, -455, it appears that the -482, -455 and SstI APOC-III gene polymorphisms are not major contributors to the risk of dyslipidemia in the population of northern France.
|
10781646 |
2000 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOC3 polymorphisms might be associated with both dyslipidemia and lipoatrophy in HAART-treated patients.
|
18240956 |
2008 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.
|
21939545 |
2011 |
|
Dyslipidemias
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We evaluated the contribution of APOC3 -482C-->T, -455T-->C, and 3238C-->G; epsilon 2 and epsilon 4 alleles of APOE; and TNF -238G-->A to dyslipidemia and lipoatrophy by longitudinally modeling >2600 lipid determinations and 2328 lipoatrophy assessments in 329 ART-treated patients during a median follow-up period of 3.4 years.
|
15809899 |
2005 |
|
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
We discuss APOC3-targeted experimental treatments for dyslipidemia.
|
30753100 |
2019 |
|
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of the study was to scrutinize the effect of Clematichinenoside (AR) on dyslipidemia-induced atherosclerosis and explore its capability on expression of Peroxisome proliferator-activated receptor-α (PPAR-alpha), apolipoprotein A-I (APOA1) and A-II (APOA2), and suppression of apolipoprotein C-III (APOC3) genes and proteins.
|
25979856 |
2015 |
|
Dyslipidemias
|
0.100 |
Biomarker
|
group |
BEFREE |
Complex metabolic disorders of apolipoproteins are present in T2DM, such as high plasma apoB, apoC‑II, apoC‑III and apoE concentrations, and low plasma apoA‑I and apoM concentrations, which are associated with dyslipidaemia and interrelated complications.
|
29152661 |
2017 |
|
Dyslipidemias
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and fenofibric acid (FA) in individuals with mixed dyslipidemia.
|
22236405 |
2012 |